{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:24:59Z","timestamp":1770513899758,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00322","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T23:54:41Z","timestamp":1496188481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel"],"prefix":"10.3389","volume":"8","author":[{"given":"Tim A.","family":"Kanters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Stevanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold G.","family":"Vulto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1007\/s10198-014-0595-3","article-title":"Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries","volume":"15","author":"Brodszky","year":"2014","journal-title":"Eur. J. Health Econ."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0126105","DOI":"10.1371\/journal.pone.0126105","article-title":"The cost of Ankylosing Spondylitis in the UK using linked routine and patient-reported survey data","volume":"10","author":"Cooksey","year":"2015","journal-title":"PLoS ONE"},{"key":"B4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.crohns.2013.03.011","article-title":"Governing board and operational board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)","volume":"7","author":"Danese","year":"2013","journal-title":"J. Crohns. Colitis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/ecco-jcc\/jjw090","article-title":"Changes in biosimilar knowledge among European Crohn's Colitis Organization (ECCO) members: an updated survey","volume":"10","author":"Danese","year":"2016","journal-title":"J. Crohns. Colitis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"J. Crohns. Colitis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J. Crohns. Colitis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrrheum.2015.110","article-title":"Biosimilars in rheumatology: current perspectives and lessons learnt","volume":"11","author":"D\u00f6rner","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","article-title":"The changing landscape of biosimilars in rheumatology","volume":"75","author":"D\u00f6rner","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jbspin.2004.12.009","article-title":"Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNF\u03b1 biological therapy in France","volume":"72","author":"Fautrel","year":"2005","journal-title":"Joint Bone Spine"},{"key":"B11","volume-title":"Common Disease with Uncommon Treatment: European Guideline Variations and Access to Innovative Therapies for Rheumatoid Arthritis","author":"Hockley","year":"2012"},{"key":"B12","volume-title":"Expert Opinion","year":"2012"},{"key":"B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000449088","article-title":"Experience with biosimilar infliximab (Remsima) in Norway","volume":"35","author":"Jahnsen","year":"2017","journal-title":"Dig. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"A525","DOI":"10.1016\/j.jval.2014.08.1655","article-title":"Budget impact analysis of introducing biosimilar infliximab for the treatment of auto immune disorders in five European countries","volume":"17","author":"Jha","year":"2014","journal-title":"Value Health"},{"key":"B15","first-page":"S512","article-title":"5 year budget impact analysis of biosimilar infliximab for the treatment of rheumatoid arthritis in UK, Italy, France and Germany","volume":"11","author":"Kim","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B16","volume-title":"Access to Innovative Treatments in Rheumatoid Arthritis in Europe","author":"Kobelt","year":"2009"},{"key":"B17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/art.21989","article-title":"Primary therapist model for patients referred for rheumatoid arthritis rehabilitation: a cost-effectiveness analysis","volume":"55","author":"Li","year":"2006","journal-title":"Arthritis Care Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1365-2036.2010.04466.x","article-title":"The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy","volume":"32","author":"Lichtiger","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S0149-2918(00)87984-9","article-title":"Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo","volume":"22","author":"Mathias","year":"2000","journal-title":"Clin. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","article-title":"Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices\u2014budget impact analysis","volume":"10","author":"Mauskopf","year":"2007","journal-title":"Value Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"A558","DOI":"10.1016\/j.jval.2013.08.1465","article-title":"Introduction of an infliximab biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland","volume":"16","author":"McCarthy","year":"2013","journal-title":"Value Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1002\/art.11439","article-title":"Direct medical costs and their predictors in patients with rheumatoid arthritis","volume":"48","author":"Michaud","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B23","first-page":"57","article-title":"Challenges for the adoption of future biosimilars","volume":"13","author":"Moors","year":"2007","journal-title":"Eur. J. Hosp. Pharmacy Pract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.3748\/wjg.v21.i6.1728","article-title":"Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe","volume":"21","author":"Rencz","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B25","volume-title":"Rote Liste 2013","year":"2013"},{"key":"B26","doi-asserted-by":"publisher","first-page":"A639","DOI":"10.1016\/j.jval.2015.09.2276","article-title":"Budget impact analysis of an etanercept biosimilar for the treatment of rheumatoid arthritis in Europe","volume":"18","author":"Ruff","year":"2015","journal-title":"Value Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11523-011-0192-7","article-title":"Biosimilars and market access: a question of comparability and costs?","volume":"7","author":"Simoens","year":"2012","journal-title":"Targ. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study","volume":"63","author":"van der Valk","year":"2014","journal-title":"Gut"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1136\/ard.2004.033977","article-title":"Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity","volume":"64","author":"Verstappen","year":"2005","journal-title":"Ann. Rheum. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00322\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T23:54:46Z","timestamp":1496188486000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00322\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":30,"alternative-id":["10.3389\/fphar.2017.00322"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00322","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,31]]},"article-number":"322"}}